

AUTHOR'S CORRECTION

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

KANYIN E. ZHANG, ELLEN WU, AMY K. PATICK, BRADLEY KERR, MARK ZORBAS,
ANGELA LANKFORD, TAKUO KOBAYASHI, YUKI MAEDA, BHASKER SHETTY,
AND STEPHANIE WEBBER

*Pfizer Global Research and Development, La Jolla, California, and Central Pharmaceutical Research Institute,
Japan Tobacco Inc., Osaka 569, Japan*

Volume 45, no. 4, p. 1086–1093, 2001. Page 1090, column 1, lines 1 to 5: “did not show any . . . or its metabolites” should read “showed no significant differences in exposure to either the parent drug or its metabolites between the first dose and steady state (Table 3); however, this analysis was not designed or powered to rule out modest changes in clearance or exposure, and the trend for increased M8-to-nelfinavir concentration ratio on day 28 may reflect modest induction of metabolism during multiple dosing.”